A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration resistant Prostate Cancer Associated with Homologous Recombination Deficiency
|Effective start/end date||4/1/18 → 4/30/23|
- CLOVIS ONCOLOGY, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.